
1/24

Figure 1



= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP FOR EXAMPLE: DIMETHOXYTRITYL (DMT)


= CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR

INVERTED DEOXYABASIC SUCCINATE)

= CLEAVABLE LINKER


(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR INVERTED DEOXYABASIC SUCCINATE)




INVERTED DEOXYABASIC SUCCINATE LINKAGE

GLYCERYL SUCCINATE LINKAGE

Figure 2





WO 2005/045038 PCT/US2004/027231

4/24 Figure 4 SENSE STRAND (SEQ ID NO 789) ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N) 5'--3' 3'-L-(N_sN) NNNNNNNNNNNNNNNNNNN -5' ANTISENSE STRAND (SEQ ID NO 790 ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N) SENSE STRAND (SEO ID NO 791) ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-OM EXCEPT POSITIONS (N N) 5'--3' B 3'--5' ANTISENSE STRAND (SEQ ID NO 792) ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N) SENSE STRAND (SEQ ID NO 793) ALL PYRIMIDINES = 2'-O-ME OR 2'-FLUORO EXCEPT POSITIONS (N N) 5'--3' 3'--5' ANTISENSE STRAND (SEQ ID NO 794) ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) SENSE STRAND (SEQ ID NO 795) ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSÌTIONS (N N) AND ALL PURINES = 2'-DEOXY -3' D L-(N_sN) NNNNNNNNNNNNNNNNNNNN 3'--5' ANTISENSE STRAND (SEQ ID NO 792) ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N) SENSE STRAND (SEQ ID NO 796) ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) 5'<u>-</u> -3' E -5' 3'-ANTISENSE STRAND (SEQ ID NO 792) ALL PYRIMIDINES = 2'-FLUORO AND ALL PURÌNES = 2'-O-ME EXCEPT POSITIONS (N N) SENSE STRAND (SEQ ID NO 795) ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSÌTIONS (N N) AND ALL PURINES = 2'-DEOXY 5'--3' F 3'--5' ANTISENSE STRAND (SEQ ID NO 797) ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES

B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT

L = GLYCERYL or B THAT IS OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE that is optionally absent

Figure 5

5/24


		SENSE STRAND (SEQ ID NO 798))
A	5'-	B-AUGACCAUCGUGGCCUUCC <i>TT</i> -B	-3'
		L-T _S T UACUGGUAGCACCGGAAGG	-5'
		ANTISENSE STRAND (SEQ ID NO 799)	
	Ĺ	(22(22))	J
В		SENSE STRAND (SEQ ID NO 800))
	5'-	<u>augaccaucguggccuuccT_ST</u>	-3'
	₹ 3'-	L-T _S Tu <u>a</u> cuggu <u>a</u> gc <u>a</u> ccgg <u>a</u> agg	-5' >
		ANTISENSE STRAND (SEQ ID NO 801)	
			J
C	Ì	SENSE STRAND (SEQ ID NO 802)	ĺ
	5'-	B-AuGAccAucGuGGccuuccTT-B	-3'
	ൃ 3'-	L-T _S T u A c u G G u A G c A c c G G A A G G	-5' }
		ANTISENSE STRAND (SEQ ID NO 803)	
			J
D		SENSE STRAND (SEQ ID NO 804)	ń
	<i>E</i> ,	,	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	B-AuGAccAucGuGGccuuccTT-B	-3'
	3'-	L-T _S Tu <u>a</u> cuggu <u>a</u> gc <u>a</u> ccgg <u>a</u> agg	-5'
		ANTISENSE STRAND (SEQ ID NO 801)	
	7	SENSE STRAND (SEQ ID NO 805)	7
E	5'-	B-AuGAccAucGuGGccuuccTT-B	-3'
	√ 3'-	L-T _S Tu <u>a</u> cuggu <u>a</u> gc <u>a</u> ccgg <u>aagg</u>	-5' >
		ANTISENSE STRAND (SEQ ID NO 801)	
	Ì	SENSE STRAND (SEQ ID NO 804)	ĺ
F	5'-	B-AuGAccAucGuGGccuuccTT-B	-3'
	3'-	L-T _S TuAcuGGuAGcAccGGAAGG	-5' >
		ANTISENSE STRAND (SEQ ID NO 806)	
	Ĺ	ITALIC UPPER CASE = DECVY	J

lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro italic lower case = 2'-deoxy-2'-fluoro underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY

B = ABASIC, INVERTED ABASIC, INVERTED
NUCLEOTIDE OR OTHER TERMINAL
CAP THAT IS OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE OPTIONALLY PRESENT
L = GLYCERYL MOIETY or B OPTIONALLY PRESENT



i, i




Figure 8





Figure 9: Target site Selection using siRNA



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy




Figure 12: Phosphorylated siNA constructs

SiNA (n) Asymmetric hairpin Asymmetric duplex siNA Phosphates can be modified as described herein


12/24

(n) = number of base pairs (e.g. 3-18 bp)

combination of other modifications herein

13/24

Figure 13: 5'-phosphate modifications








Figure 14A: Duplex forming oligonucleotide constructs that utilize Palindrome or repeat sequences



Non-palindromic Complementary
Sequence of (ii) to 3'-end of complementary
sequence
■ Self assembly of self complementary
■ strands to form duplex construct

<u>(i</u>



16/24

Figure 14C: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly




Figure 14D: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly and inhibition






Figure 15: Duplex forming oligonucleotide constructs that utilize artificial palindrome or repeat sequences


utilize modified nucleotides (shown as X, Y) sequence and result in the formation of a Design Complementary Sequence and that interact with a portion of the target Identify Target Nucleic Acid sequence (e.g., 14 to 24 nucleotides in length) (e.g., 2 to 12 nucleotides) at 3'-end palindrome/repeat sequence (dashed portion) XXXXX XXXXX

Append inverse sequence of Complementary region to 3'-end of palindrome/repeat sequence

Hybridize self complementary strands to form duplex siNA construct









 \mathbf{m}


20/24




21/24



WO 2005/045038 PCT/US2004/027231





24/24

Figure 21: Example of multifunctional siNA targeting two regions within the same target nucleic acid sequence

